Table 2 Associated constants of hf-gate.
From: Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment
| Â | \({{\boldsymbol{V}}}_{{\bf{h}}(h{\boldsymbol{\infty }})}\) | k h | \({{\boldsymbol{V}}}_{{{\bf{h}}}_{{{\boldsymbol{f}}}_{{\boldsymbol{\tau }}}}}\) | \({{\boldsymbol{a}}}_{{{\bf{h}}}_{{\boldsymbol{f}}}}\) | \({{\boldsymbol{b}}}_{{{\bf{h}}}_{{\boldsymbol{f}}}}\) | \({{\boldsymbol{c}}}_{{{\bf{h}}}_{{\boldsymbol{f}}}}\) | \({{\boldsymbol{d}}}_{{{\bf{h}}}_{{\boldsymbol{f}}}}\) |
|---|---|---|---|---|---|---|---|
WT | −78.929 | 4.409 | −50.000 | 0.980 | 117.620 | 96.289 | 0.314 |
A1656D | −69.476 | 4.898 | −36.690 | 13.568 | −181.416 | 2.772 | 0 |
Mexiletine | −71.958 | 5.486 | −17.961 | 12.620 | 13.700 | 82.331 | 0 |
Flecainide | −73.533 | 8.220 | 53.838 | 11.021 | 168.053 | 35.413 | 0 |
Ranolazine | −70.530 | 4.866 | 14.483 | 19.607 | 30.882 | 84.456 | 1.745 |
